Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib in preventing skin cancer in participants exposed to ultraviolet light
NCT00025051Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-melanoma skin cancer (NMSC) comparing Celecoxib with Placebo (2 arms). Primary endpoints: Ultraviolet-induced erythema at 120 days and Surrogate biomarkers of potential neoplastic change at 120 days. Status: withdrawn.
02
Drugs
celecoxib
03
Conditions
non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT00025051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025051.